Nektar Therapeutics (NKTR) Operating margin 2016–2025
Nektar Therapeutics (NKTR) operating margin by fiscal year — reported operating income divided by reported revenue.
-253.7%FY2025 · since FY2016: -68.2% → -253.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -253.7% | -146.8 pp |
| FY2024 | -106.9% | +185.7 pp |
| FY2023 | -292.6% | +116.0 pp |
| FY2022 | -408.6% | +29.1 pp |
| FY2021 | -437.8% | -159.8 pp |
| FY2020 | -278.0% | +105.9 pp |
| FY2019 | -383.9% | -441.6 pp |
| FY2018 | 57.6% | +77.0 pp |
| FY2017 | -19.4% | +48.8 pp |
| FY2016 | -68.2% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More NKTR financial trends
NKTR RevenueNKTR Net incomeNKTR Net marginNKTR Gross profitNKTR Gross marginNKTR Operating incomeNKTR Operating cash flowNKTR Free cash flowNKTR Capital expendituresNKTR Return on equityNKTR Stock buybacksNKTR Dividends paidNKTR Total assetsNKTR Total liabilitiesNKTR Shareholders’ equityNKTR overview →